U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07480382) titled 'Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC' on March 14.
Brief Summary: This study evaluates a novel "Dual-Conversion" strategy (mechanical volume conversion via LVD plus biological conversion via cTACE, Tislelizumab, and Lenvatinib) for patients with initially unresectable right-sided hepatocellular carcinoma (HCC). The primary goal is to assess the rate of successful conversion to R0 resection and the safety profile of this multi-modal approach.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Initially Unresectable Hepatocellular Carcinoma
Intervention:
PROCEDURE: Liver V...